Gastrointestinal cancer
Drug research and approvals for gastrointestinal cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 3,495 studies of gastrointestinal cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 10 drug trials for it since 2013.
- Recruiting worldwide: 3,495
- Trials authorized in Canada: 10
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 3,495 recruiting on ClinicalTrials.gov ↗- Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced…NCT07619521 · Phase 1 / Phase 2 · National Cancer Institute (NCI) · starts Jun 1, 2027
- Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard…NCT07551596 · Phase 2 · National Cancer Institute (NCI) · starts May 25, 2027
- A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal…NCT06424522 · Not applicable · Ohio State University Comprehensive Cancer Center · starts Feb 15, 2027
- Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or…NCT07271355 · Phase 3 · City of Hope Medical Center · starts Jan 4, 2027
- Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)NCT07433673 · Phase 2 · Columbia University · starts Jan 1, 2027
- Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal…NCT07750158 · Phase 3 · Exelixis · starts Dec 18, 2026
- Testing the Effects of Exercise on Colorectal Cancer Development After Treatment With Pelvic Radiation Therapy for…NCT07790718 · Not applicable · City of Hope Medical Center · starts Dec 16, 2026
- ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic…NCT07444541 · Phase 1 / Phase 2 · Anova Innovation Limited · starts Dec 1, 2026
- SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-METNCT07873450 · Phase 1 / Phase 2 · Full-Life Technologies UK Limited · starts Dec 1, 2026
- Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion…NCT07789184 · Phase 3 · Hua Huang, MD, PhD · starts Dec 1, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Feb 19, 2025 | A phase 2 nonrandomized, open-label, multisite study to evaluate the safety and efficacy of raludotatug deruxtecan in participants with gastrointestinal cancersRALUDOTATUG DERUXTECAN (R-DXD (MK-5909) | Merck & Co. (MSD) | Ongoing |
| Sep 26, 2024 | A phase 1/2 study to evaluate the safety and efficacy of patritumab deruxtecan in gastrointestinal cancersPATRITUMAB (MK-1022, U3-1402) | Merck & Co. (MSD) | Ongoing |
| May 23, 2024 | A phase 1/2 study to evaluate the safety and efficacy of mk-2870 monotherapy or in combination with other anticancer agents in gastrointestinal cancersMK-2870 (SACITUZUMAB TIRUMOTECAN) / 5-FLUOROURACIL (5-FU) / CALCIUM FOLINATE | Merck & Co. (MSD) | Ongoing |
| Mar 26, 2024 | A phase 1b study evaluating the safety, tolerability, pharmacokinetics, and efficacy of amg 193 in combination with other therapies in subjects with advanced…AMG 193 | Amgen | Pending |
| Dec 22, 2022 | A phase Ia/ib, open label, multicentre, dose escalation study of bi 905711 in combination with chemotherapy followed by expansion cohorts in patients with…BI 905711 | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Pending |
| Feb 9, 2022 | A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous…ABELACIMAB | ANTHOS THERAPEUTICS, INC. | Closed |
| Apr 25, 2019 | A phase 3 randomized placebo-controlled double-blind study of romiplostim for the treatment of chemotherapy-induced thrombocytopenia in patients receiving…NPLATE | Amgen | Ongoing |
| Mar 13, 2019 | Phase Ib study of gevokizumab in combination with standard of care anticancer therapies in patients with metastatic colorectal cancer, gastroesophageal cancer…GEVOKIZUMAB (VPM087) / PACLITAXEL | Novartis Pharmaceuticals Corporation | Closed |
| Jun 2, 2014 | An open-labeled, multicenter phase II study of cabazitaxel in refractory metastatic gastric or gastroesophageal adenocarcinomaCABAZITAXEL | DR YOO-JOUNG KO | Pending |
| Oct 18, 2013 | A phase Ib clinical study of bbi608 in combination with standard chemotherapies in adult patients with advanced gastrointestinal cancerNAPABUCASIN (BBI608)/ BEVACIZUMAB | SUMITOMO DAINIPPON PHARMA ONCOLOGY INC | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA